Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 5/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PI4KA | P42356 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.36 |
| ▸ | TUBB | P07437 | 1/20 | 0.36 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.36 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23902695 | 0.92 | PRKCI (0.44) | PRKCIHTR6GRM2NTSR1HTR7 | |
| SCHEMBL30365011 | 0.92 | PRKCI (0.44) | PRKCIHTR6GRM2NTSR1HTR7 | |
| SCHEMBL30364834 | 0.90 | CNR2 (0.49) | PRKCIHTR6GRM2NTSR1PIK3CD | |
| SCHEMBL23902660 | 0.90 | CNR2 (0.49) | PRKCIHTR6GRM2NTSR1PIK3CD | |
| SCHEMBL30364809 | 0.89 | GRM2 (0.42) | PRKCIHTR6GRM2NTSR1HTR7 | |
| SCHEMBL23902715 | 0.89 | GRM2 (0.42) | PRKCIHTR6GRM2NTSR1HTR7 | |
| SCHEMBL31324655 | 0.88 | HTR7 (0.46) | PRKCIHTR6GRM2HTR7PIK3CD | |
| SCHEMBL23902712 | 0.87 | BRD4 (0.43) | PRKCIHTR6GRM2NTSR1CNR1 | |
| SCHEMBL23902671 | 0.87 | PRKCI (0.40) | PRKCIHTR6GRM2NTSR1HTR7 | |
| SCHEMBL30364846 | 0.87 | BRD4 (0.43) | PRKCIHTR6GRM2NTSR1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867201-B2 | Heteroaromatic bicyclic derivatives useful as anticancer agents | PFIZER INC (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1396489-A1 | Heteroaromatic bicyclic derivatives useful as anticancer agents | Pfizer Products Inc. (US) | 2004-03-10 | — | — | EP | disclosed |
| EP-1029853-B1 | Heteroaromatic bicyclic derivatives useful as anticancer agents | PFIZER PROD INC (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030055049-A1 | Heteroaromatic bicyclic derivatives useful as anticancer agents | PFIZER INC. | 2003-03-20 | — | — | US | disclosed |
| US-6465449-B1 | SUCH AS (6-(4-(6-AMINO-3-AZA-BICYCLO(3.1.0)HEX-3-YLMETHYL)-PHENYL)-QUINAZOLIN-4-YL) -(4-PHENOXY-PHENYL)-AMINE | PFIZER INC. | 2002-10-15 | — | — | US | disclosed |
| EP-1029853-A1 | Heteroaromatic bicyclic derivatives useful as anticancer agents | Pfizer Products Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055049-A1 | Heteroaromatic bicyclic derivatives useful as anticancer agents | RCC1, CCNA1, MCL1 | PRKCI 4021/4885HTR6 3211/4885GRM2 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.